Menu

 

Letter

Avastin versus Lucentis

Approve bevacizumab for use in eye disease in cash strapped times

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e4806 (Published 23 July 2012)
Cite this as: BMJ 2012;345:e4806

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ilias Georgalas, consultant ophthalmic surgeon1,
  2. Chrysanthi Koutsandrea, consultant vitreoretinal surgeon1
  1. 1Department of Ophthalmology, University of Athens, 11527 Athens, Greece
  1. igeorgalas{at}yahoo.com

We agree with Godlee that the “miracle” of anti-VEGF (vascular endothelial growth factor) treatment has been overshadowed by the bevacizumab (Avastin) versus ranibuzimab (Lucentis) dispute.1

However, in our opinion, the anti-VEGF treatment versus no treatment debate is even more important. During this economic crisis, many of our patients with …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Subscribe

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

Latest comments and most commented

THIS WEEK'S POLL

Read related article

See previous polls